Presenter: Sherly Mosessian, Ph.D
SOFIE Chief Scientific Officer

Dr. Mosessian earned her bachelors degree in Biochemistry, followed by her Ph.D from UCLA Department of Molecular, Medical Pharmacology, with publications in tumor signaling, molecular imaging targets and clinical trials of Position Emission Tomography (PET) probes. In her role as the Chief Scientific Officer of SOFIE she formulates the strategic plan for scientific objectives of the organization, including leading the FAPI clinical development program.

In this session, Dr. Mosessian will help you to understand the significance of FAP as a target for imaging and therapy, highlight latest progress in FAP targeting for therapeutic use, explain advancements made with FAP targeting radioligands in imaging, and describe the clinical development and regulatory approval progress with FAP targeting radioligands